Navigation Links
Targeting memory T-cells in Type 1 diabetes
Date:9/22/2013

WA, Seattle (September 23, 2013) Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Mark R. Rigby M.D., Ph.D. from Indiana University and Riley Hospital for Children in Indianapolis and sponsored by the Immune Tolerance Network (ITN) with additional support from JDRF, are published today in The Lancet Diabetes & Endocrinology.

Alefacept, an engineered fusion protein targeting a surface molecule, CD2, found on T-lymphocytes, was the first biologic therapy approved for moderate to severe plaque psoriasis. By binding CD2, alefacept inhibits co-stimulation and induces T-cell depletion. T-cell mediated destruction of insulin producing pancreatic beta cells is a central feature of Type 1 diabetes, but targeting of CD2 has not previously been evaluated in this disease. The T1DAL trial was designed to test whether alefacept would preserve pancreatic beta cell function in newly diagnosed patients.

The Phase II T1DAL study enrolled 49 new-onset type 1 diabetic subjects, ages 12 to 35, who were randomized into two groups: 33 to alefacept and 16 to placebo. Patients received two twelve week courses (separated by a 12 week pause) of either alefacept or placebo. Twelve months from the start of the study, patients underwent a mixed meal tolerance test to measure the C-peptide response (a measure of insulin production). The primary endpoint, a 2-hour C-peptide response, did not show statistically significant differences between treatment and placebo groups; however, a secondary endpoint, a 4-hour C-peptide response, was significantly higher at 12 months in the treatment group compared to the placebo group. Other secondary endpoints including insulin use and rate of hypoglycemic events were significantly lower at 12 months in the alefacept treated group.

Although the primary endpoint was not met, these encouraging results of key secondary endpoints suggest a disease-modifying effect of alefacept. Additional support for alefacept's therapeutic role comes from analysis of T-cell subtypes of treated patients that showed that effector T cells were primarily targeted while sparing protective regulatory T cells. Lead investigator Dr. Mark Rigby suggests, "The T1DAL study is the first to use an agent to specifically deplete the cells which attack the pancreas in type 1 diabetes, the memory and effector T cells. We also found that regulatory T cells are not depleted with this therapy, suggesting that immune re-education can take place."

Longer 24 month follow-up of the subjects in this study is in progress to evaluate the potential for durable efficacy of the alefacept treatment. "Unfortunately our study was not able to enroll the goal number of participants due to drug availability which prevented more definitive conclusions at this point," said Dr. Rigby. "We are eagerly awaiting additional data over the next year which will help us determine if targeting memory T cells will help those with Type 1 diabetes make insulin for extended periods."


'/>"/>

Contact: Philip Bernstein, Ph.D.
ITNCommunications@immunetolerance.org
240-235-6132
Immune Tolerance Network
Source:Eurekalert

Related medicine news :

1. Targeting aggressive prostate cancer
2. Nanodrug targeting breast cancer cells from the inside adds weapon: Immune system attack
3. Cancer research brief: Targeting pancreatic cancer drug resistance
4. Targeting errant immune system enzyme kills myelodysplastic cells
5. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offer Improved hCG Diet Plans Capable of Targeting Stubborn Belly Fat Now Linked With Decreased Bone Density
6. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Now Offer New Weight Loss Diets that Educate Patients, Targeting Weight Gained During Childhood and Adolescence
7. Overcoming resistance to anti-cancer drugs by targeting cell powerhouses
8. Study Shows Dual Targeting of HER2 and HR-positive Metastatic Breast Cancer Improves Survival Rates
9. Drugs targeting blood vessels may be candidates for treating Alzheimers
10. Changing shape makes chemotherapy drugs better at targeting cancer cells
11. Cleveland Clinic study shows bariatric surgery restores pancreatic function by targeting belly fat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... ... April 30, 2016 , ... Create an abstract shape ... distort and manipulate three-dimensional shapes with ease all within Apple Motion . ... polygons, polygon texture animation, opacity texture animation, overall shape texture displacement, twist, camera ...
(Date:4/30/2016)... ... April 30, 2016 , ... The Hacking Medicine ... program to critically evaluate and rank health-focused applications and connected devices for better ... independent, unbiased and accurate information to help accelerate patient and provider adoption of ...
(Date:4/30/2016)... ... April 30, 2016 , ... Dr. Trevor Gardner, President of ... signed a multifaceted agreement which will allow for the research and development of ... Natural and Applied Sciences, Allied Health and Nursing will work together to develop ...
(Date:4/30/2016)... CA (PRWEB) , ... April 30, 2016 , ... “Aging well is a challenge for all of us, but there ... NCMA’s Dr. Parul T. Kohli . “Research is showing more and more that there are ... of disease and disability as we age.” Top priorities Dr. Kohli’s recommends for her patients include;, ...
(Date:4/29/2016)... (PRWEB) , ... April 30, 2016 , ... ... engineer of patented products, announces the Pick Up Springboard, an automotive invention that ... Light Truck Manufacturing industry is worth $162 billion," says Scott Cooper, CEO and ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... TURIN, Italy , April 27, 2016 ... MR-guided linear accelerator (MR-linac) platform will be the focal ... annual meeting of the European Society for Radiotherapy & ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and ... a physician to clearly see the patient,s anatomy in ...
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
(Date:4/27/2016)... 27, 2016 At the Sachs ... of a Phase 2 clinical study of its lead ... undergoing cochlear implantation (CI) surgery. This large, placebo-controlled, double-blind, ... Germany and France ... at the time of surgery. "Despite advances in cochlear ...
Breaking Medicine Technology: